Send all pre-paid doses of AstraZeneca despite plans to delay supply: EU

The commissioner stressed that the EU required AstraZeneca to provide a report regarding the company's activities, adding that the bloc would hold the second round of consultations with AstraZeneca

Topics
European Union | Coronavirus Vaccine | AstraZeneca

ANI  |  Europe 

Medics, vaccination, vaccine, coronavirus, covid, healthcare workers, hospitals, doctors, nurses, patients, vaccination, coronavirus, covid, vaccine
Medics at a vaccination booth preparing for the first round of vaccination drive | Photo: PTI

The has demanded UK pharmaceutical company deliver all the pre-paid doses against the coronavirus and provide a report on the company's activities, following its recent decision to delay the supply of the vaccine to the EU, European Commissioner for Health and Food Safety Stella Kyriakides said on Monday.

Earlier in the day, Kyriakides asked to explain the delays in deliveries, assuring that the goal to have 70 per cent of the EU population inoculated by the summer remained unchanged.

"The wants the ordered and pre-financed doses to be delivered as soon as possible and we want our contract to be fully fulfilled," Stella Kyriakides said in a press statement.

The commissioner stressed that the EU required to provide a report regarding the company's activities, adding that the bloc would hold the second round of consultations with AstraZeneca this evening.

"The has pre-financed the development of the vaccine and its production and wants to see the return. The European Union wants to know exactly which doses have been produced whereby AstraZeneca so far, and if, or to whom, they have been delivered. These questions were also discussed today in the joint steering board of the commission and the 27 member states with AstraZeneca," Kyriakides said, adding that "the answers of the company have not been satisfactory so far and that's why a second meeting is scheduled for tonight."

The EU has an agreement with AstraZeneca for up to 400 million doses of its vaccine, which was developed in conjunction with the University of Oxford.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on European Union
First Published: Tue, January 26 2021. 06:25 IST
RECOMMENDED FOR YOU